Cost Utility of Vaccination Against COVID-19 in Brazil
The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system. A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contai...
Gespeichert in:
Veröffentlicht in: | Value in health regional issues 2022-09, Vol.31, p.18-24 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 24 |
---|---|
container_issue | |
container_start_page | 18 |
container_title | Value in health regional issues |
container_volume | 31 |
creator | Fernandes, Ricardo Ribeiro Alves Santos, Marisa da Silva Magliano, Carlos Alberto da Silva Tura, Bernardo Rangel Macedo, Luana Schroeder Damico Nascimento Padila, Matheus Piccin França, Ana Cláudia Wekmuller Braga, Andressa Araujo |
description | The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system.
A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs).
The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis.
The results of the analysis by age group can help in the preparation of a vaccination prioritization plan.
•This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending. |
doi_str_mv | 10.1016/j.vhri.2022.01.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8935121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212109922000942</els_id><sourcerecordid>2644009619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoKuof8CB79LJrJsl-BETQ-gmCF-015GtrynajybZQf70ptUUvzmUG5n3fGR6ETgEXgKG6mBaL9-AKggkpMBQY8x10SAiQHACT3c2MOT9AJzFOcaqaYdrgfXRAS0rKitNDVI18HLK3wXVuWGa-zcZSa9fLwfk-u55I16f16GX8dJsDz1yf3QT55bpjtNfKLtqTn36E3u7vXkeP-fPLw9Po-jnXrCyH3DRGQVOXQLmsDSgKShGGWyWJMVgboEZz09aKt01pMTMS6rKBVrWskowpeoSu1rkfczWzRtt-CLITH8HNZFgKL534u-ndu5j4hWg4LYFACjj_CQj-c27jIGYuatt1srd-HgWpGEvsKuBJStZSHXyMwbbbM4DFirmYihVzsWIuMIjkS6az3w9uLRvCSXC5FtiEaeFsEFE722trXLB6EMa7__K_AUdtkio</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644009619</pqid></control><display><type>article</type><title>Cost Utility of Vaccination Against COVID-19 in Brazil</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Fernandes, Ricardo Ribeiro Alves ; Santos, Marisa da Silva ; Magliano, Carlos Alberto da Silva ; Tura, Bernardo Rangel ; Macedo, Luana Schroeder Damico Nascimento ; Padila, Matheus Piccin ; França, Ana Cláudia Wekmuller ; Braga, Andressa Araujo</creator><creatorcontrib>Fernandes, Ricardo Ribeiro Alves ; Santos, Marisa da Silva ; Magliano, Carlos Alberto da Silva ; Tura, Bernardo Rangel ; Macedo, Luana Schroeder Damico Nascimento ; Padila, Matheus Piccin ; França, Ana Cláudia Wekmuller ; Braga, Andressa Araujo</creatorcontrib><description>The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system.
A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs).
The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis.
The results of the analysis by age group can help in the preparation of a vaccination prioritization plan.
•This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (<59, 60-75, and >75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending.</description><identifier>ISSN: 2212-1099</identifier><identifier>ISSN: 2212-1102</identifier><identifier>EISSN: 2212-1102</identifier><identifier>DOI: 10.1016/j.vhri.2022.01.009</identifier><identifier>PMID: 35325693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Brazil - epidemiology ; Cost-Benefit Analysis ; cost-utility analysis ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines - therapeutic use ; health technology assessment ; HTA ; Humans ; Quality of Life ; Themed Section: COVID-19 ; Vaccination ; vaccines</subject><ispartof>Value in health regional issues, 2022-09, Vol.31, p.18-24</ispartof><rights>2022 International Society for Health Economics and Outcomes Research</rights><rights>Copyright © 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</rights><rights>2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. 2022 International Society for Health Economics and Outcomes Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</citedby><cites>FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35325693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernandes, Ricardo Ribeiro Alves</creatorcontrib><creatorcontrib>Santos, Marisa da Silva</creatorcontrib><creatorcontrib>Magliano, Carlos Alberto da Silva</creatorcontrib><creatorcontrib>Tura, Bernardo Rangel</creatorcontrib><creatorcontrib>Macedo, Luana Schroeder Damico Nascimento</creatorcontrib><creatorcontrib>Padila, Matheus Piccin</creatorcontrib><creatorcontrib>França, Ana Cláudia Wekmuller</creatorcontrib><creatorcontrib>Braga, Andressa Araujo</creatorcontrib><title>Cost Utility of Vaccination Against COVID-19 in Brazil</title><title>Value in health regional issues</title><addtitle>Value Health Reg Issues</addtitle><description>The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system.
A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs).
The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis.
The results of the analysis by age group can help in the preparation of a vaccination prioritization plan.
•This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (<59, 60-75, and >75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending.</description><subject>Brazil - epidemiology</subject><subject>Cost-Benefit Analysis</subject><subject>cost-utility analysis</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines - therapeutic use</subject><subject>health technology assessment</subject><subject>HTA</subject><subject>Humans</subject><subject>Quality of Life</subject><subject>Themed Section: COVID-19</subject><subject>Vaccination</subject><subject>vaccines</subject><issn>2212-1099</issn><issn>2212-1102</issn><issn>2212-1102</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMoKuof8CB79LJrJsl-BETQ-gmCF-015GtrynajybZQf70ptUUvzmUG5n3fGR6ETgEXgKG6mBaL9-AKggkpMBQY8x10SAiQHACT3c2MOT9AJzFOcaqaYdrgfXRAS0rKitNDVI18HLK3wXVuWGa-zcZSa9fLwfk-u55I16f16GX8dJsDz1yf3QT55bpjtNfKLtqTn36E3u7vXkeP-fPLw9Po-jnXrCyH3DRGQVOXQLmsDSgKShGGWyWJMVgboEZz09aKt01pMTMS6rKBVrWskowpeoSu1rkfczWzRtt-CLITH8HNZFgKL534u-ndu5j4hWg4LYFACjj_CQj-c27jIGYuatt1srd-HgWpGEvsKuBJStZSHXyMwbbbM4DFirmYihVzsWIuMIjkS6az3w9uLRvCSXC5FtiEaeFsEFE722trXLB6EMa7__K_AUdtkio</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Fernandes, Ricardo Ribeiro Alves</creator><creator>Santos, Marisa da Silva</creator><creator>Magliano, Carlos Alberto da Silva</creator><creator>Tura, Bernardo Rangel</creator><creator>Macedo, Luana Schroeder Damico Nascimento</creator><creator>Padila, Matheus Piccin</creator><creator>França, Ana Cláudia Wekmuller</creator><creator>Braga, Andressa Araujo</creator><general>Elsevier Inc</general><general>International Society for Health Economics and Outcomes Research. Published by Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220901</creationdate><title>Cost Utility of Vaccination Against COVID-19 in Brazil</title><author>Fernandes, Ricardo Ribeiro Alves ; Santos, Marisa da Silva ; Magliano, Carlos Alberto da Silva ; Tura, Bernardo Rangel ; Macedo, Luana Schroeder Damico Nascimento ; Padila, Matheus Piccin ; França, Ana Cláudia Wekmuller ; Braga, Andressa Araujo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-d8db1875139a7d1b31bb240fba2dd0cd13dc9df7b9f85e04da17581fbf46a44b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brazil - epidemiology</topic><topic>Cost-Benefit Analysis</topic><topic>cost-utility analysis</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines - therapeutic use</topic><topic>health technology assessment</topic><topic>HTA</topic><topic>Humans</topic><topic>Quality of Life</topic><topic>Themed Section: COVID-19</topic><topic>Vaccination</topic><topic>vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernandes, Ricardo Ribeiro Alves</creatorcontrib><creatorcontrib>Santos, Marisa da Silva</creatorcontrib><creatorcontrib>Magliano, Carlos Alberto da Silva</creatorcontrib><creatorcontrib>Tura, Bernardo Rangel</creatorcontrib><creatorcontrib>Macedo, Luana Schroeder Damico Nascimento</creatorcontrib><creatorcontrib>Padila, Matheus Piccin</creatorcontrib><creatorcontrib>França, Ana Cláudia Wekmuller</creatorcontrib><creatorcontrib>Braga, Andressa Araujo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Value in health regional issues</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernandes, Ricardo Ribeiro Alves</au><au>Santos, Marisa da Silva</au><au>Magliano, Carlos Alberto da Silva</au><au>Tura, Bernardo Rangel</au><au>Macedo, Luana Schroeder Damico Nascimento</au><au>Padila, Matheus Piccin</au><au>França, Ana Cláudia Wekmuller</au><au>Braga, Andressa Araujo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost Utility of Vaccination Against COVID-19 in Brazil</atitle><jtitle>Value in health regional issues</jtitle><addtitle>Value Health Reg Issues</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>31</volume><spage>18</spage><epage>24</epage><pages>18-24</pages><issn>2212-1099</issn><issn>2212-1102</issn><eissn>2212-1102</eissn><abstract>The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system.
A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs).
The vaccines showed incremental cost-utility ratios ranging from R$−23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis.
The results of the analysis by age group can help in the preparation of a vaccination prioritization plan.
•This is the first economic evaluation performed with COVID-19 vaccines from the perspective of the Brazilian public health system.•The analysis used real-world data on mortality and outpatient and hospital treatment, which represent the context of the first year of the pandemic in Brazil.•The study allowed for a comparison of the cost-utility ratios of 3 different vaccines used in Brazil, taking into account 3 age groups (<59, 60-75, and >75 years old), and demonstrating the impact of price and number of doses on the efficiency of health spending.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35325693</pmid><doi>10.1016/j.vhri.2022.01.009</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2212-1099 |
ispartof | Value in health regional issues, 2022-09, Vol.31, p.18-24 |
issn | 2212-1099 2212-1102 2212-1102 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8935121 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Brazil - epidemiology Cost-Benefit Analysis cost-utility analysis COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - therapeutic use health technology assessment HTA Humans Quality of Life Themed Section: COVID-19 Vaccination vaccines |
title | Cost Utility of Vaccination Against COVID-19 in Brazil |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T04%3A46%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20Utility%20of%20Vaccination%20Against%20COVID-19%20in%20Brazil&rft.jtitle=Value%20in%20health%20regional%20issues&rft.au=Fernandes,%20Ricardo%20Ribeiro%20Alves&rft.date=2022-09-01&rft.volume=31&rft.spage=18&rft.epage=24&rft.pages=18-24&rft.issn=2212-1099&rft.eissn=2212-1102&rft_id=info:doi/10.1016/j.vhri.2022.01.009&rft_dat=%3Cproquest_pubme%3E2644009619%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644009619&rft_id=info:pmid/35325693&rft_els_id=S2212109922000942&rfr_iscdi=true |